Pharmaceutical firm Lundbeck's Laboratories are buzzing, busy with the work spearheaded by the company's Head of Research and Development Johan Luthman, as a new generation of migraine drugs are taking shape.
After Lundbeck acquired Alder Biopharmaceuticals in 2019 for USD 1.95bn in 2019, migraine treatment has become one of Lundbeck's biggest focus areas. Since then, the migraine preventive treatment, Vyepti, has reached the market.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.